AllSquare Wealth Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-150
| Closed | -$876 | – | 566 |
|
|
2022
Q4 | $876 | Hold |
150
| – | – | ﹤0.01% | 479 |
|
|
2022
Q3 | $1K | Hold |
150
| – | – | ﹤0.01% | 492 |
|
|
2022
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 496 |
|
|
2022
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 497 |
|
|
2021
Q4 | $0 | Hold |
150
| – | – | ﹤0.01% | 514 |
|
|
2021
Q3 | $0 | Hold |
150
| – | – | ﹤0.01% | 519 |
|
|
2021
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 491 |
|
|
2021
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 488 |
|
|
2020
Q4 | $2K | Hold |
150
| – | – | ﹤0.01% | 440 |
|
|
2020
Q3 | $1K | Hold |
150
| – | – | ﹤0.01% | 459 |
|
|
2020
Q2 | $1K | Hold |
150
| – | – | ﹤0.01% | 458 |
|
|
2020
Q1 | $1K | Hold |
150
| – | – | ﹤0.01% | 444 |
|
|
2019
Q4 | $1K | Hold |
150
| – | – | ﹤0.01% | 443 |
|
|
2019
Q3 | $1K | Sell |
150
-100
| -40% | -$1.06K | ﹤0.01% | 444 |
|
|
2019
Q2 | $3K | Hold |
250
| – | – | ﹤0.01% | 418 |
|
|
2019
Q1 | $3K | Hold |
250
| – | – | ﹤0.01% | 423 |
|
|
2018
Q4 | $3K | Hold |
250
| – | – | ﹤0.01% | 415 |
|
|
2018
Q3 | $4K | Hold |
250
| – | – | ﹤0.01% | 425 |
|
|
2018
Q2 | $4K | Buy |
+250
| New | +$4.86K | ﹤0.01% | 424 |
|
AllSquare Wealth Management's CNCE Position: Q1 2023 in Review
AllSquare Wealth Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2023, closing a stake of 150 shares — an estimated $876 sold.
AllSquare Wealth Management first reported a position in CNCE in Q2 2018 and held it in 19 quarters. The position peaked at $4K in Q3 2018. 0 funds tracked by Wall St. Rank hold CNCE as of Q1 2023.
- AllSquare Wealth Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2023 after selling out during the quarter.
- AllSquare Wealth Management sold 150 Concert Pharmaceuticals, Inc. shares in Q1 2023, an estimated $876.
- AllSquare Wealth Management first reported a position in Concert Pharmaceuticals, Inc. in Q2 2018 and held it in 19 quarters.
- AllSquare Wealth Management's Concert Pharmaceuticals, Inc. position peaked at $4K in Q3 2018.
- 0 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2023.
Based on AllSquare Wealth Management's 13F filing for Q1 2023, filed 2 May 2023.